Corcept Therapeutics Incorporated
CORT
$71.68
$1.221.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.93% | 39.94% | 39.67% | 33.04% | 26.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.93% | 39.94% | 39.67% | 33.04% | 26.51% |
| Cost of Revenue | 43.74% | 52.45% | 44.67% | 31.18% | 29.16% |
| Gross Profit | 30.75% | 39.77% | 39.60% | 33.06% | 26.47% |
| SG&A Expenses | 63.94% | 52.13% | 36.04% | 27.33% | 17.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.13% | 43.19% | 37.59% | 33.83% | 28.10% |
| Operating Income | -9.03% | 28.59% | 47.14% | 30.41% | 21.56% |
| Income Before Tax | -3.54% | 29.65% | 48.49% | 37.87% | 30.94% |
| Income Tax Expenses | -90.81% | 10.13% | 18.82% | 69.66% | 73.95% |
| Earnings from Continuing Operations | 13.53% | 33.04% | 55.19% | 33.15% | 24.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.53% | 33.04% | 55.19% | 33.15% | 24.89% |
| EBIT | -9.03% | 28.59% | 47.14% | 30.41% | 21.56% |
| EBITDA | -8.90% | 28.09% | 45.67% | 29.17% | 20.91% |
| EPS Basic | 11.77% | 32.10% | 56.08% | 36.72% | 30.14% |
| Normalized Basic EPS | -4.55% | 30.12% | 51.03% | 43.02% | 37.56% |
| EPS Diluted | 8.96% | 29.99% | 55.50% | 36.10% | 29.23% |
| Normalized Diluted EPS | -6.92% | 28.31% | 50.44% | 42.97% | 38.07% |
| Average Basic Shares Outstanding | 1.23% | -0.34% | -1.87% | -3.37% | -4.61% |
| Average Diluted Shares Outstanding | 4.93% | 1.42% | -1.48% | -3.24% | -4.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |